LATAM Fabry Disease Market
Over the forecast period, the LATAM fabry disease market is anticipated to be driven by an increase in academic research into the causes of and treatments for the condition. For instance, according to a National Center for Biotechnology Information report from September 2019, a research team had carried out a study to thoroughly comprehend fabry sickness and its therapy. The essay emphasised the developments in our knowledge of the fabry illness. The page provides information about fabry disease treatments that are currently being studied, such as substrate reduction therapies, mRNA-based therapies, and gene therapies, as well as treatments that are currently available, such as enzyme replacement and chaperone therapy.
The LATAM fabry illness market is anticipated to expand as a result of regulatory authorities’ approval of medications for the treatment of fabry disease. For instance, the biotechnology company Amicus Therapeutics said on August 10, 2018, that the FDA has authorised Galafold (migalastat) 123 mg capsules. Galafold is an oral medication used to treat individuals with fabry disease. The first novel therapy authorised to treat Fabry disease is Galafold, the first oral medication for the condition.
Get a Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/5249
Over the projected period, the coronavirus disease (COVID-19) pandemic is anticipated to restrain the growth of the LATAM fabry disease market. The WHO Weekly Epidemiological Update on COVID-19 reports a decline in the number of new cases for the week of August 15–21, 2022. As a result, 6.4 million fatalities and 593 million confirmed cases have been reported globally as of August 21, 2022.
The COVID-19 pandemic’s impact on clinical trials will likely limit the development of the LATAM fabry disease industry. For instance, the drug manufacturing industries had to halt clinical trials as a result of COVID-19 restrictions put in place by governments in the majority of the world’s countries, according to data published on November 19, 2021 by Society for Human Resource Management, a membership association for human resources professionals. People’s freedom of movement was restricted by COVID-19, and as a result, transportation services were interrupted, which led to a lack of workers and raw materials in the companies that manufacture drugs.
The LATAM fabry disease market will expand over the projected period as a result of a published article calling for better care for fabry disease patients in Brazil. For instance, patients with fabry disease in Brazil are at danger because to inadequate treatment, according to a Brazilian Journal of Nephrology paper that was published on February 10, 2021. According to the report, Brazil’s capacity to provide fabry disease patients with treatments like enzyme replacement therapy is under jeopardy. By expanding the facilities for treatment, supplying more medications, upgrading the therapy, etc., this is anticipated to provide chance for the market for fabry illness to develop in Brazil.
The LATAM fabry disease market is anticipated to increase at a CAGR of 6.7% from 2022 to 2030 as a result of expansion in promising areas, particularly Brazil. While the majority of the market was dominated by Argentina.
The LATAM fabry disease market is anticipated to expand as a result of recent success in treating patients with the condition with a novel, sophisticated therapy called gene therapy. For instance, the patient Darren Bidulka responded favourably to stem cell gene therapy for fabry illness, according to data released on March 1, 2021 by the California Institute for Regenerative Medicine. The Foothills Medical Center in Calgary treated the first patient with fabry illness using gene therapy in 2017, and the patient’s outcome demonstrated the effectiveness of the treatment. The market for fabry disease treatment is anticipated to be driven by the effective treatment of fabry illness by innovative therapies.
Resverlogix, Amicus Therapeutics, Inc., Moderna Therapeutics Inc., Sanofi-Aventis U.S. LLC, Novartis AG, GlaxoSmithKline plc, Pfizer Inc., Mendelics, Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceuticals U.S.A., Inc. are significant market participants in the LATAM fabry disease market.
Get customized report as per requirement @ https://www.coherentmarketinsights.com/insight/request-customization/5249
- LATAM Fabry Disease Market, By Therapy Type:
- Enzyme Replacement Therapy
- Agalsidase Beta (Fabrazyme)
- Agalsidase Alfa (Replagal)
- Pegunigalsidase Alfa (PRX-102, Phase III)
- Chaperon Therapy
- Migalastat (Galafold Phase III)
- Substrate Reduction Therapy
- Lucerastat (Phase III)
- Venglustat (Phase III)
- LATAM Fabry Disease Market, By Route of Administration:
- LATAM fabry disease market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
- Enzyme Replacement Therapy
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Recent Product Launch/Approval
- Key Strategies Adopted by Market Players
- PEST Analysis
- Mergers and Acquisitions
- Market Dynamics
Direct Buy This Premium Research Report Here Up to 45% OFF – https://www.coherentmarketinsights.com/promo/buynow/5249
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States
Phone: U.S.: +1-206-701-6702